IDH Inhibitors in AML
This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
Cytogenetic and Mutational Landscape of AML
IDH Mutations as a Target in AML
Current Status of IDH Inhibitors
Exposure to Mutated IDH1 Inhibitor Effectively Inhibits the Oncometabolite 2-HG
Enasidenib in R/R AML Phase 1/2 Study Design[a] and Updated Results[b]
Evolution of Response With Enasidenib
Enasidenib in R/R AML: Overall Survival
Phase 1 Study of Ivosidenib in IDH1-Mutant R/R AML
Ivosidenib in IDH1-Mutant R/R AML
Impact of IDH1 Mutation Clearance Status With Ivosidenib
IDH Inhibitor Toxicities
IDH Inhibitor Toxicities
Identification and Treatment of Clinical IDH-Differentiation Syndrome
Indirect Hyperbilirubinemia With Enasidenib
QT Prolongation With Ivosidenib
Phase 1 Study of Induction + Enasidenib/Ivosidenib Study Design
Phase 1 Study of Induction + Enasidenib/Ivosidenib Best Responses
Phase 1 Study of Induction + Enasidenib/Ivosidenib Overall Survival
HOVON 150AML Study Design
Ivosidenib or Enasidinib With Azacitidine for Unfit Patients With ND AML
Ivosidenib + AZA Treatment Duration, Response, and Disposition
Frontline Study of AZA ± Ivosidenib
Incorporating IDH Mutation Testing in the Clinic
Impact of Co-Occurring Mutations at Start of Enasidinib
No Apparent Impact of IDH VAF on Likelihood of Response
Clinical Role of IDH Inhibitors Today
Abbreviations
Abbreviations (cont)
Abbreviations (cont)